Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring ELANE mutations.

Mutations in the ELANE gene, encoding the neutrophil elastase (NE) protein, are responsible for most CyN cases and approximately 25 % of CN cases. In CN and in CyN, a median of 2.8 % of CD34+ cells were early CD49f+ hematopoietic stem cells (eHSC) that did not express ELANE and thus escape from the unfolded protein response (UPR) caused by mutated NE. In CyN, the CD49f+ cells respond to G-CSF with a significant upregulation of the hematopoietic stem-cell-specific transcription factors, C/EBP/, MLL1, HOXA9, MEIS1, and HLF during the ascending arm of the cycle, resulting in the differentiation of myeloid cells to mature neutrophils at the cycle peak. However, NE protein released by neutrophils at the cycle's peak caused a negative feedback loop on granulopoiesis through the proteolytic digestion of G-CSF. In contrast, in CN patients, CD49f+ cells failed to express mRNA levels of HSC-specific transcription factors mentioned above. Rescue of C/EBP//expression in CN restored granulopoiesis.

[1]  J. Palmblad,et al.  The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action , 2023, HemaSphere.

[2]  A. Lupas,et al.  A topological refactoring design strategy yields highly stable granulopoietic proteins , 2022, Nature Communications.

[3]  C. Eaves,et al.  Post-natal conservation of human blood and marrow-specific CD34+ hematopoietic phenotypes. , 2022, Experimental hematology.

[4]  N. Salomonis,et al.  Induced cell-autonomous neutropenia systemically perturbs hematopoiesis in Cebpa enhancer-null mice , 2021, Blood advances.

[5]  G. Sauvageau,et al.  HLF Expression Defines the Human Hematopoietic Stem Cell State. , 2021, Blood.

[6]  J. Skokowa.  Circumventing Mutation to Nix Neutropenia. , 2021, The New England journal of medicine.

[7]  M. Konantz,et al.  iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. , 2021, Cell stem cell.

[8]  K. Welte,et al.  New insights into the pathomechanism of cyclic neutropenia , 2020, Annals of the New York Academy of Sciences.

[9]  B. Ballester,et al.  ReMap 2020: a database of regulatory regions from an integrative analysis of Human and Arabidopsis DNA-binding sequencing experiments , 2019, Nucleic Acids Res..

[10]  L. Kanz,et al.  Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation. , 2019, Experimental hematology.

[11]  K. Welte,et al.  Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia , 2019, Front. Immunol..

[12]  Berthold Göttgens,et al.  Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors , 2018, Nature Communications.

[13]  Yaniv Lubling,et al.  Single-cell characterization of haematopoietic progenitors and their trajectories in homeostasis and perturbed haematopoiesis , 2018, Nature Cell Biology.

[14]  P. Newburger,et al.  Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia. , 2017, The New England journal of medicine.

[15]  D. Dale,et al.  Elastase inhibitors as potential therapies for ELANE‐associated neutropenia , 2017, Journal of leukocyte biology.

[16]  P. Krebsbach,et al.  The Role of Integrin α6 (CD49f) in Stem Cells: More than a Conserved Biomarker. , 2017, Stem cells and development.

[17]  L. Steinmetz,et al.  Human haematopoietic stem cell lineage commitment is a continuous process , 2017, Nature Cell Biology.

[18]  K. Sachs,et al.  Distinct signaling programs control human hematopoietic stem cell survival and proliferation. , 2017, Blood.

[19]  K. Welte,et al.  Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML. , 2016, Blood.

[20]  K. Welte,et al.  ELANE mutant–specific activation of different UPR pathways in congenital neutropenia , 2016, British journal of haematology.

[21]  Patrick J. Paddison,et al.  Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. , 2015, The Journal of clinical investigation.

[22]  P. Rosenberg,et al.  The diversity of mutations and clinical outcomes for ELANE-associated neutropenia , 2015, Current opinion in hematology.

[23]  Pablo Menendez,et al.  HOXA9 promotes hematopoietic commitment of human embryonic stem cells. , 2014, Blood.

[24]  J. Hess,et al.  C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis , 2014, Proceedings of the National Academy of Sciences.

[25]  Marie S. Hasemann,et al.  C/EBPα Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent Progenitors , 2014, PLoS genetics.

[26]  D. Steinemann,et al.  Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. , 2013, Blood.

[27]  A. Moore,et al.  An MLL-dependent network sustains hematopoiesis , 2013, Proceedings of the National Academy of Sciences.

[28]  D. Tenen,et al.  C/EBPa controls acquisition and maintenance of adult hematopoietic stem cell quiescence , 2013, Nature Cell Biology.

[29]  A. Hero,et al.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells. , 2012, Blood.

[30]  Igor Jurisica,et al.  Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment , 2011, Science.

[31]  Philip S Rosenberg,et al.  Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy , 2010, British journal of haematology.

[32]  B. K. Thakur,et al.  Neutrophil elastase is severely down-regulated in severe congenital neutropenia independent of ELA2 or HAX1 mutations but dependent on LEF-1. , 2009, Blood.

[33]  S. Nagata,et al.  Essential role of C/EBPα in G‐CSF‐induced transcriptional activation and chromatin modification of myeloid‐specific genes , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[34]  R. Humphries,et al.  Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. , 2007, Genes & development.

[35]  R. Humphries,et al.  Hox genes in hematopoiesis and leukemogenesis , 2007, Oncogene.

[36]  S. Salipante,et al.  Neutrophil elastase in cyclic and severe congenital neutropenia. , 2007, Blood.

[37]  A. Schambach,et al.  LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia , 2006, Nature Medicine.

[38]  I. Weissman,et al.  Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. , 2005, Blood.

[39]  L. Druhan,et al.  Proteolytic cleavage of granulocyte colony‐stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony‐stimulating factor receptor , 2003, American journal of hematology.

[40]  J. Melenhorst,et al.  Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. , 2003, Blood.

[41]  R. Person,et al.  Role of neutrophil elastase in bone marrow failure syndromes: molecular genetic revival of the chalone hypothesis , 2003, Current opinion in hematology.

[42]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[43]  K. Calvo,et al.  Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: Potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Feng-Qian Li,et al.  Characterization of Mutant Neutrophil Elastase in Severe Congenital Neutropenia* , 2001, The Journal of Biological Chemistry.

[45]  K. Welte,et al.  Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias , 1994, British journal of haematology.

[46]  J. Gabrilove,et al.  Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. , 1989, The New England journal of medicine.

[47]  D. Dale,et al.  Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. , 1989, The New England journal of medicine.

[48]  A. Morley,et al.  Cyclic hemopoiesis and feedback control. , 1979, Blood cells.

[49]  K. Welte,et al.  CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation. , 2020, Methods in molecular biology.

[50]  K. Welte,et al.  Cyclic and chronic neutropenia. , 2011, Cancer treatment and research.

[51]  R. Humphries,et al.  Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. , 2002, Experimental hematology.

[52]  D. Tenen,et al.  CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. , 1998, Molecular and cellular biology.

[53]  S. Asano,et al.  Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. , 1989, Blood.

[54]  G. V. von Schulthess,et al.  Cyclic neutropenia (CN): a clue to the control of granulopoiesis. , 1982, Blood.